Figure 1.
Early, late and delayed toxicities with car-t cell therapy and bispecific antibodies in multiple myeloma.

Early, late and delayed toxicities with car-t cell therapy and bispecific antibodies in multiple myeloma.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal